title: Prognostic Significance of Monocytes and Monocytic Myeloid-Derived Suppressor Cells in Diffuse Large B-Cell Lymphoma Treated with R-CHOP.
abstract: OBJECTIVE
  To evaluate the prognostic significance of monocytes and monocytic myeloid-derived suppressor cells (M-MDSCs) for patients with diffuse large B-cell lymphoma (DLBCL) under R-CHOP chemotherapy.
  
  
  METHODS
  Flow cytometry (FCM) was applied to measure M-MDSCs (CD14+ HLA-DRlow/- M-MDSCs).
  
  
  RESULTS
  Analysis of 144 patients with DLBCL under R-CHOP treatment showed that the 5-year overall survival rate was 61.09% (95% CI: 43.72%-72.56%) and the average survival time of patients with monocytes (%) ≥ 8% was shorter than those with monocytes (%) < 8% (P = 0.0036). Further stratified analysis suggested that the average survival time of patients with monocytes (%) ≥ 8% was shorter than patients with monocytes (%) < 8% in the moderate outcome group (R-IPI = 1, 2) (P = 0.0168) and in the poorest outcome group (R-IPI > 2) (P = 0.0397), meanwhile, there was no significant difference in survival of patients with monocytes (%) ≥ 8% compared to patients with monocytes (%) < 8% in the best outcome group (R-IPI = 0) (P = 0.3106). Both of monocytes (%) and M-MDSCs were decreased in different R-IPI groups after 4-course of R-CHOP chemotherapy (P < 0.05).
  
  
  CONCLUSIONS
  Our results indicated that monocytes (%) and M-MDSCs combined with R-IPI may be a simple and efficient immunological index to evaluate prognosis.
authors.affiliation: Hematology Department, The Second Hospital of Lanzhou University, Lanzhou, China.
authors.forename: Chongyang
authors.initials: C
authors.lastname: Wu
authors.forename: Xiangyang
authors.initials: X
authors.lastname: Wu
authors.forename: Xiaoning
authors.initials: X
authors.lastname: Liu
authors.forename: Peiqi
authors.initials: P
authors.lastname: Yang
authors.forename: Juan
authors.initials: J
authors.lastname: Xu
authors.forename: Ye
authors.initials: Y
authors.lastname: Chai
authors.forename: Qi
authors.initials: Q
authors.lastname: Guo
authors.forename: Zhiping
authors.initials: Z
authors.lastname: Wang
authors.forename: Liansheng
authors.initials: L
authors.lastname: Zhang
mesh_terms: D000328:Adult; D000368:Aged; D058846:Antibodies, Monoclonal, Murine-Derived / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D053208:Kaplan-Meier Estimate; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009000:Monocytes / Q000187:drug effects* / Q000378:metabolism; D000072737:Myeloid-Derived Suppressor Cells / Q000187:drug effects* / Q000378:metabolism; D011241:Prednisone / Q000008:administration & dosage; D011379:Prognosis; D012074:Remission Induction; D016896:Treatment Outcome; D014750:Vincristine / Q000008:administration & dosage; D055815:Young Adult
chemical_list: D058846:Antibodies, Monoclonal, Murine-Derived; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone